肠道微生物群-大脑轴:阿尔茨海默病病理学的新前沿
Meenakshi Dhanawat1, Garima Malik2, Kashish Wilson2
1Amity Institute of Pharmacy, Amity University Haryana, Gurugram 122413, India.
CNS & neurological disorders drug targets
|July 5, 2024
概括
阿尔茨海默氏症 (AD) 是一个主要的全球健康问题. 新兴研究强调了肠道微生物群-肠道-大脑轴.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,是导致痴呆的主要原因,影响全球数百万人.
- 目前的治疗主要针对胆固醇系统或粉样蛋白积累,成功程度有限.
- 肠道微生物群在维持生理恒温中起着至关重要的作用,并与包括神经退行性疾病在内的各种疾病有关.
研究的目的:
- 审查微生物群-肠-大脑轴对阿尔茨海默病发病因子的影响.
- 探索肠道失调和AD之间的联系.
主要方法:
- 对调查微生物群-肠-大脑轴和阿尔茨海默病的研究进行文献综述.
- 分析关于肠道微生物群在神经退行性疾病中的作用的科学数据.
主要成果:
- 在阿尔茨海默病患者中经常观察到肠道失调和胃肠道失调.
- 微生物群-肠道-大脑轴促进肠道微生物与中枢神经系统之间的双向通信.
结论:
- 肠道微生物群-肠道-大脑轴是阿尔茨海默病发病的一个重要因素.
- 了解这一轴可能为AD提供新的治疗点.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Role of Neurotransmitters in Memory
510
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
510
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177


